ABSTRACT
Localized scleroderma (morphea) is a disease characterized by thickening and induration of the skin and subcutaneous tissue due to excessive collagen accumulation. The reason is not known exactly. Although localized scleroderma is known as a disease limited to the skin and subcutaneous tissue, rare cases with internal organ involvement have also been reported. Herein a young case with synovitis and fasciitis in the hands will be presented while being followed up with morphea.
References
1Morfea. TürkDermatolojiDerneği Hasta BilgilendirmeBroşürü. http://www.turkdermatoloji.org
2Makay BB, Ünsal E. LineerSkleroderma. Tepecik Eğit Hast Derg 2005;15:1-11.
3Audrey M. Nelson, Localized sclerodermas. In: Cassidy JT, Petty RE, editors. T extbook of Pediatric Rheumatology, 4th edition, Philadelphia: WB Saunders Company, 2001, pp 535-43.
4Peterson LS, Nelson AM, Su WPD, Mason T, O’Fallon WM, Gabriel SE. The epidemiology of morphoea (localised scleroderma) in Olmsted County 1960- 1993. J Rheum 1997;24:73-80.
5Koca SS, Demir BK. Lineer Lokalize Skleroderma ve En Coup De Sabre Lokalize Skleroderması. TurkiyeKlinikleri J Rheumatol-Special Topics 2014;7:57-61.
6Guitart J, Micali G, Salomon LM. Localized scleroderma. In: P.J. Clements and D.E. Furst, Editors, Systemic Sclerosis, Williams & Wilkins, Philadelphia, PA (1996), pp. 65-79.
7Restrepo JF, Guzman R, Rodriguez G, lglesias A. Expressian of transforming growth factor-beta and platelet-derived growth factor in linear scleroderma. Biomedica 2003;23:408-15.
8Falanga V, Medsger TA Jr, Reichlin M, Rednan GP. Linear scleroderma. Clinical spectrum, prognosis, and laboratory abnormalities. Ann Intern Med 1986;104:849-57.
9Falanga V, Medsger TA Jr, Reichlin M. Antinuclear and anti-single-stranded DNA antibodies in morphea and generalized morphea. Arch Dermatol 1987;123:350-3.
10Sa to S, Fujimato M, Hasegawa M. Takehara K. Antiphospholipid antibody in Joealised scleroderma. Ann Rheum Dis 2003;62:771-4.
11Masaki Nagai, Minoru Hasegawa, Kazuhiko Takehara, and Shinichi Sato. Novel autoantibody to Cu/Zn superoxide dismutase in patients with localized scleroderma. J Inuest Dermatol 2004;122:594-601.
12Torres JE, Sanchez JL. Histopathologic differentiation between localized and systemic scleroderma. Am J Dermatopathol 1998;20:242-5.
13Soma Y, Tamaki T, Kikuchi K, et al. Coexistence of morphea and systemic sclerosis. Dermatology 1993;186:103-5.
14Maricq HR. Capillary abnormalities, Raynaud’s phenomenon, and systemic seleresis in patients with localized scleroderma. Arch Dermatol 1992;128:630-2.
15Peterson LS, Nelson AM, Su WPD, Mason T, O’Fallon WM, Gabriel SE. The epidemiology of morphoea (localised scleroderma) in Olmsted County 1960-1993. J Rheum 1997;24:73-80.
16Mertens JS, Marieke MB, Seyger Rogier M, et al. Morphea and Eosinophilic Fasciitis: An Update. Am J Clin Dermatol 2017;18:491-512.
17Zisova LG, Abadjieva CI, Obreshkova EV, Chernev GK, Vutova NI. Association of eosinophilic fasciitis with morphea. Folia Med (Plovdiv) 2014;56:220-4.
18Petkow AG, Bienias AK. Systemic involvement in localized scleroderma/morphea. Clin Dermatol 2015;33,556-62.
